Expand Clinical Capabilities Throughout Central and Eastern Europe
The countries in Central and Eastern Europe provide ample opportunity for life sciences companies, especially in terms of clinical development. The number of treatment-naive patients in the region makes it an ideal location to host clinical studies. In fact, the population of Central and Eastern European countries exceeds that of either the United States or the five largest Western European markets combined. Furthermore, there is a lower saturation of competing trials within the region compared to other, more developed markets.
Besides a large patient population, Central and Eastern Europe offer the drug and device industries a convenient location — especially for European-based countries — to conduct clinical studies. The region has a long history of clinical development, making it easier to find and train skilled investigators.
Use this study as a resource to design and prepare your company’s clinical trials in Central and Eastern Europe. The report addresses, in detail, the challenges and clinical development opportunities that these emerging markets provide. It provides detailed benchmark metrics for Russia, Poland, the Balkans, Bulgaria, Romania, Turkey and Ukraine, all in one place. Learn the advantages and challenges that each of these countries present. Use these data and best practices to avoid common pitfalls and solidify your clinical strategy:
Improve Patient Access
Russia and Poland offer a distinct advantage as emerging markets: access to treatment-naive patients. Recruitment and retention are strong in these countries as well. This report will guide your decision-making process as you determine how to run a trial in a Central or Eastern European nation.
Protect Intellectual Property
IP issues can be daunting when working in an emerging market. This study shows you how to work with local partners to navigate culture and regulations, avoid the threat of corruption and protect your intellectual property.
Tap Geographic and Cultural Proximity
Russia, Poland and the other countries profiled in this report offer the advantage of being neighbors to Western Europe. This means that the local investigator knowledge base is similar to that of Western European countries, and EU-EC guidelines for GCP are becoming more commonplace. Learn about the other advantages that the central and eastern European countries offer to clinical development teams.
To know more about this report & to buy a copy please visit:
http://www.visionshopsters.com/product/16441/Emerging-Markets-Clinical-Development-Series-Eastern-Europe.html